Travere Therapeutics

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Travere Therapeutics reports robust earnings, eyes market expansion opportunities

Travere Therapeutics is on a solid financial footing with promising drug launches and clinical advancements. While facing regulatory and competitive challenges, the company's strategic focus on market expansion and product utilization presents significant growth opportunities. With a strong cash position and ongoing clinical developments, Travere is well-positioned for future success.

Travere Therapeutics reports strong Q1 performance amidst FILSPARI launch

Travere Therapeutics' Q1 performance was driven by strong FILSPARI sales and positive physician adoption.
Despite challenges in FSGS and HCU programs, regulatory flexibility and patient community evolution present opportunities.
Physician interest in FILSPARI data and payer coverage quality are key strengths for the successful launch.
Monitoring metrics and upcoming study readouts offer avenues for growth and optimization in rare disease treatments.

Travere Therapeutics reports strong Q2 performance and growth opportunities

Travere Therapeutics showcased strong performance with revenue growth and positive clinical results across key programs.
The company's strategic focus on core pipeline programs and divestment of non-core assets has bolstered its financial position.
Challenges include competitive dynamics, regulatory uncertainties, and the need for disciplined spending amidst growth opportunities.
Overall, Travere is well-positioned for future growth with promising pipeline programs and a focus on market expansion.

Travere Therapeutics reports strong Q3 performance and strategic advancements

Travere Therapeutics showcased strong operational and financial performance in Q3 2023, with advancements in key programs and positive regulatory engagements.
The company's strategic focus on rare disease treatments, patient education efforts, and regulatory alignment position it well for future growth.
Challenges in revenue forecasting, market positioning, and evolving treatment landscapes highlight areas for ongoing strategic focus and adaptation.
Opportunities in market expansion, revenue growth, program advancements, and patient engagement present avenues for continued success and impact.

Travere Therapeutics reports strong revenue growth and strategic advancements

Travere Therapeutics had a successful year with strong revenue growth and progress in key treatments
Filspari's performance in IgAN drove demand and revenue, positioning the company for further growth
Challenges include the DUPLEX study results and low innovation in the prescriber base
Opportunities lie in sNDA submissions, ongoing studies, and potential for full approval and broader label

Travere Therapeutics excels in Q1 with FILSPARI market success

Travere Therapeutics showcased strong performance and financial stability in Q1 2024, driven by FILSPARI's successful commercial launch and positive patient outcomes.
The company's focus on market adoption, regulatory milestones, and engagement strategies positions it for continued growth and potential inclusion in treatment guidelines.
Challenges in inventory management, regulatory compliance, and strategic alignment with stakeholders need to be addressed to capitalize on growth opportunities and maintain market leadership.

Travere Therapeutics excels in Q2 2024, poised for growth

Travere Therapeutics delivered a strong performance in Q2 2024, driven by FILSPARI's growth and positive regulatory developments.
While facing challenges in regulatory processes and market expansion, the company's solid financial position and ongoing initiatives position it well for future success.
Opportunities for growth abound through potential approvals, global expansion, and advancements in drug development programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023, at 10:15 a.m. ET.

Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference

LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present clinical data from the Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU), at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in Jerusalem, Israel, August 29 – September 1, 2023.

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023

Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Naomi Eichenbaum - Vice President-Investor Relations Eric Dube - Chief Executive Officer Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - Chief Financial Officer Bill Rote - Senior Vice President of Research & Development Conference Call Participants Malcolm Kuno - JPMorgan Tyler Van Buren - TD Cowen Greg Harrison - Bank of America Joseph Schwartz - Leerink Partners Maurice Raycroft - Jefferies Tim Lugo - William Blair Vamil Divan - Guggenheim Securities Laura Chico - Wedbush Securities Alex Thompson - Stifel Ed Arce - H.C. Wainright Operator Good day, and welcome to the Travere Therapeutics Second Quarter 2023 Financial Results and Corporate Update Conference Call.

Travere Therapeutics, Inc. (TVTX) Q2 2023 Earnings Call Transcript

Although the revenue and EPS for Travere (TVTX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Travere (TVTX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

•   Received 417 new patient start forms for FILSPARI™(sparsentan) in the second quarter 2023, reflecting continued strong demand from nephrologists and patients with IgA nephropathy (IgAN)

Travere Therapeutics Reports Second Quarter 2023 Financial Results

LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

bluebird bio

Viking Therapeutics

Bluebird Bio could have a game-changer with sickle cell disease therapy lovo-cel. Wall Street thinks Traverse Therapeutics stock could nearly double over the next 12 months.

3 Small-Cap Stocks That Could Be Big-Time Winners

Travere Therapeutics Inc (NASDAQ: TVTX) has been a disappointment for shareholders since early May but a JPMorgan analyst expects it to recover over the next 18 months. Travere Therapeutics shares have a 65% upside On Friday, Anupam Rama assumed coverage of the biotech stock with an “overweight” rating.

Biotech stock Travere Therapeutics is trading at a deep discount: JPMorgan

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2023 financial results on Thursday, August 3, 2023, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Travere Therapeutics to Report Second Quarter 2023 Financial Results

Mirum Pharmaceuticals Inc

FOSTER CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)-- #liverdisease--Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics.

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics

LOS ANGELES, CA / ACCESSWIRE / July 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

NEW YORK , July 6, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Travere Therapeutics, Inc.: The investigation focuses on whether Travere issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain Travere investors.

INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Travere Therapeutics, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: TVTX)

LOS ANGELES, CA / ACCESSWIRE / July 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK , July 3, 2023 /PRNewswire/ -- Attention Travere Therapeutics, Inc. ("Travere") (NASDAQ: TVTX) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into Travere and certain of its officers and directors regarding potential securities fraud. The investigation concerns, in part, the below: The investigation focuses on whether Travere issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

TVTX ALERT: The Law Offices of Vincent Wong Investigate Travere Therapeutics, Inc. for Potential Violations of Securities Laws

LOS ANGELES, CA / ACCESSWIRE / July 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

NEW YORK , June 30, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Travere Therapeutics, Inc. (NASDAQ: TVTX) To be contacted by a member of our team, fill out the form: https://claimyourloss.com/securities/travere-class-action-loss-submission-form/?id=41541&from=4 Further details on the investigation: The investigation focuses on whether Travere issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud.

TVTX FRAUD ALERT: Jakubowitz Law is Investigating Travere Therapeutics, Inc. in Connection with Potential Violations of Federal Securities Laws

NEW YORK , June 29, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere") (NASDAQ: TVTX) concerning possible violations of federal securities laws. The investigation focuses on whether Travere issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

TVTX INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Travere Therapeutics, Inc.

NEW YORK , June 27, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Travere Therapeutics, Inc. ("Travere") (NASDAQ: TVTX) violated federal securities laws. CURRENT INVESTIGATION DETAILS:The investigation focuses on whether Travere issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

TVTX NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Travere Therapeutics, Inc.

Chinook Therapeutics

Novartis

Vera Therapeutics

In light of a Novartis NVS, -0.94% deal to acquire Chinook Therapeutics Inc. KDNY, +58.09%, which is developing treatments for a rare kidney disease, two other companies focused on the same disease look even more attractive, analysts said Monday.

Novartis deal for Chinook makes kidney-treatment competitors more attractive, analysts say

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present nine abstracts, including the interim analysis from the ongoing Phase 3 PROTECT Study evaluating FILSPARI™ (sparsentan) versus an active comparator in IgA nephropathy (IgAN), at the 60th ERA Congress in Milan, Italy, June 15-18, 2023. Also included in the presentations is a new analysis of the UK RaDaR Registry estimating the delay in time to kidney failure or death based on proteinuria reduction in IgAN, which has been designated among the 10 best-ranked abstracts of 2023 by ERA.

Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023

BioMarin Pharmaceutical

Gilead Sciences

Navigating the turbulent waters in the biotech space is no mean feat. With the sector's inherent volatility due to testing clinical trials and regulatory hurdles, the road toward market approval can be incredibly challenging.

3 Biotech Stocks That Could Skyrocket in the Next 12 Months

LOS ANGELES, CA / ACCESSWIRE / June 2, 2023 / Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Data from the four patients treated with the highest dose of pegtibatinase showed a clinically meaningful 67.1% mean relative reduction in total homocysteine from baseline

Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria

FILSPARI's inability to significantly change FSGS disease trajectory (eGFR) in the Phase 3 DUPLEX study raises doubts about its IgAN trial and eventual approvability in FSGS. FILSPARI's sales, largely inventory-driven, may not predict actual market potential. We downgrade to sell rating as we are bearish on the PROTECT readout and also believe the upcoming sales data won't be a meaningful enough catalyst to change the trajectory.

News for Travere Therapeutics Stock (TVTX)